Stock JSPR JASPER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-20 EDT 		5-day change 1st Jan Change
21.86 USD -5.74% Intraday chart for Jasper Therapeutics, Inc. -10.19% +177.06%
06-19 Jasper Therapeutics, Inc. Announces Board Changes CI
06-14 Jasper Therapeutics, Inc. Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jasper Therapeutics, Inc. Announces Board Changes
Jasper Therapeutics, Inc. Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4
Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise
Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023
Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
Jasper Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023
Jasper Therapeutics, Inc. Announces Board Changes
Jasper Therapeutics, Inc. Appointed Herb Cross, as Corporate Secretary
Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Jasper Therapeutics Strengthens Management Team with Key Appointments
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JSPR Stock
  4. News Jasper Therapeutics, Inc.
  5. Other languages